Reuters Health News Summary

Reuters Health News Summary

Following is a summary of current health news briefs. Lilly to launch half-price version of insulin

U.S. drugmaker Eli Lilly and Co plans to sell a half-price version of its Humalog insulin injection, as it fends off criticism about rising drug prices. Lilly said on Monday the new version would be called Insulin Lispro, while Humalog would remain available for patients who want to continue accessing it through their current insurance plans. China urges crack down on concealing African swine fever: agriculture ministry

China needs to step up its prevention and control of African swine fever, said the agriculture ministry in a statement on Monday, as the disease continues to spread across the world's top pork-producing nation. Authorities should combat illegal activities such as concealing outbreaks, selling and arbitrarily disposing of sick and dead pigs, and feeding kitchen waste to pigs, said the ministry following a meeting with 18 other ministries. Ebola treatment center in Congo reopens after attack: ministry

An Ebola treatment center at the epicenter of the current outbreak in eastern Democratic Republic of Congo has resumed operations after it was closed in response to an attack last week, the Congolese health ministry said on Sunday. The facility in the city of Butembo was one of two centers torched by unknown assailants in the space of a few days, prompting Medecins Sans Frontieres (MSF) to suspend medical activities. U.S. seeks to cut dialysis costs with more home care versus clinics

The Trump administration is working on a new payment approach for treating kidney disease that favors lower cost care at home and transplants, a change that would upend a dialysis industry that provides care in thousands of clinics nationwide. The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending.

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.